ADVFN Logo
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Quanterix Corporation

Quanterix Corporation (QTRX)

11.93
-0.47
(-3.79%)
At close: November 14 4:00PM
11.92
-0.01
( -0.08% )
After Hours: 4:02PM

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Key stats and details

Current Price
11.92
Bid
11.69
Ask
12.55
Volume
679,920
11.55 Day's Range 12.52
10.50 52 Week Range 29.70
Market Cap
Previous Close
12.40
Open
12.365
Last Trade Time
16:00:04
Financial Volume
$ 8,224,079
VWAP
12.0957
Average Volume (3m)
379,450
Shares Outstanding
38,379,033
Dividend Yield
-
PE Ratio
-14.49
Earnings Per Share (EPS)
-0.84
Revenue
122.37M
Net Profit
-32.33M

About Quanterix Corporation

Quanterix Corp is a life sciences company. It focuses on developing an ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics. The Simoa bead-based and planar array platforms designed by the company enable customers to reliably detect p... Quanterix Corp is a life sciences company. It focuses on developing an ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics. The Simoa bead-based and planar array platforms designed by the company enable customers to reliably detect protein biomarkers in low concentrations in blood, serum and other fluids which are undetectable using conventional, analog immunoassay technologies. The company has developed Simoa technology which is a method of detection of proteins and has the capability of analyzing nearly six biomarkers per test, with anticipated expansion capability. Show more

Sector
Lab Analytical Instruments
Industry
Lab Analytical Instruments
Headquarters
Wilmington, Delaware, USA
Founded
-
Quanterix Corporation is listed in the Lab Analytical Instruments sector of the NASDAQ with ticker QTRX. The last closing price for Quanterix was $12.40. Over the last year, Quanterix shares have traded in a share price range of $ 10.50 to $ 29.70.

Quanterix currently has 38,379,033 shares outstanding. The market capitalization of Quanterix is $475.90 million. Quanterix has a price to earnings ratio (PE ratio) of -14.49.

QTRX Latest News

Quanterix Releases Preliminary Financial Results for the Third Quarter of 2024

Sixth Consecutive Quarter of Double-Digit Growth Reaffirms Full Year 2024 Outlook Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultra-sensitive biomarker...

Quanterix To Report Third Quarter 2024 Financial Results on November 12, 2024

Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that it will host a conference call on Tuesday, November...

New Multi-Marker Blood Test from Lucent Diagnostics Increases the Number of Patients Receiving Early Alzheimer’s Disease Diagnostic Information

LucentADTM Complete improves on single biomarker tests, significantly reducing the intermediate zone, providing results for more patients Lucent Diagnostics, a brand of Quanterix Corporation...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-3.37-22.040549378715.2915.6711.9257184514.08142303CS
4-0.84-6.5830721003112.7615.6711.9242325013.51761084CS
12-1.27-9.6285064442813.1915.85510.9637945013.13733213CS
26-5.06-29.799764428716.9819.0610.542254113.79082305CS
52-9.97-45.545911375121.8929.710.539270317.8051296CS
156-45.18-79.124343257457.157.556.3140221118.09362899CS
260-9.63-44.68677494221.5592.576.3134198427.03500686CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
AALAmerican Airlines Group Inc
$ 0.00
(0.00%)
0
AAGRAfrican Agriculture Holdings Inc
$ 0.00
(0.00%)
0
AADRAdvisorShares Dorsey Wright ADR ETF
$ 0.00
(0.00%)
0
AADIAadi Bioscience Inc
$ 0.00
(0.00%)
0
AACGATA Creativity Global
$ 0.00
(0.00%)
0
AALAmerican Airlines Group Inc
$ 0.00
(0.00%)
0
AAGRAfrican Agriculture Holdings Inc
$ 0.00
(0.00%)
0
AADRAdvisorShares Dorsey Wright ADR ETF
$ 0.00
(0.00%)
0
AADIAadi Bioscience Inc
$ 0.00
(0.00%)
0
AACGATA Creativity Global
$ 0.00
(0.00%)
0
AALAmerican Airlines Group Inc
$ 0.00
(0.00%)
0
AAGRAfrican Agriculture Holdings Inc
$ 0.00
(0.00%)
0
AADRAdvisorShares Dorsey Wright ADR ETF
$ 0.00
(0.00%)
0
AADIAadi Bioscience Inc
$ 0.00
(0.00%)
0
AACGATA Creativity Global
$ 0.00
(0.00%)
0

QTRX Discussion

View Posts
ziggy7796 ziggy7796 2 years ago
Nice bounce from yesterday's 56% drop!!!

Ziggy
👍️ 1
XenaLives XenaLives 5 years ago
NEUROLOGY
Simoa® is not just a better way to detect CNS biomarkers
It's a 1,000-times better way

The ability to detect neurological biomarkers at ultra-low levels, which have traditionally only been detectable in cerebrospinal fluid, has the potential to transform the way brain injuries and diseases are diagnosed.

Simoa assays can detect neurological biomarkers, such as Neurofilament Light (NfL),Tau, GFAP and several otohers associated with brain injury and disease. With Simoa, these informative markers can be detected at much earlier stages, in blood, serum or plasma, enabling better understanding of the long-term effects and disease pathology without invasive measures. Quanterix has a strategic focus in neurodegeneration, neuroinflammation, traumatic brain injuries (TBI) and multiple sclerosis (MS) and is working with a rapidly growing network of academic researchers and pharmaceutical and biotech partners to drive advancements in head health research.



https://www.quanterix.com/therapeutic-areas/cns-biomarkers
👍️0
XenaLives XenaLives 5 years ago

QUANTERIX’ SIMOA TECHNOLOGY POWERS MORE THAN 85 PERCENT OF NEUROFILAMENT LIGHT BIOMARKER RESEARCH TO BE UNVEILED AT AMERICAN ACADEMY OF NEUROLOGY ANNUAL MEETING
Leading global neurology conference will feature 36 new Simoa-powered studies validating the use of Neurofilament light chain (Nf-L) as a potential diagnostic and prognostic biomarker for neurodegeneration

LEXINGTON, Mass.--(BUSINESS WIRE)--May 6, 2019-- Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced that its ultra-sensitive Simoa technology is the driving force behind 36 of the 42 – nearly 86 percent – Nf-L abstracts being presented at the American Academy of Neurology (AAN)’s Annual Meeting, taking place from May 4-10, 2019 in Philadelphia, PA. This year’s program represents a nearly four-fold increase in Nf-L research compared to last year, reinforcing the marker’s mounting value as a key indicator of neurodegenerative disease onset and progression.

“As the use cases for Nf-L grow, evidenced by the growing body of research presented at AAN, we believe that this biomarker is truly one of the most promising biomarkers for brain health with the power to completely transform the way diseases like Alzheimer’s, Multiple Sclerosis, Parkinson’s, and even brain injuries are diagnosed and treated,” said Kevin Hrusovsky, Chairman and CEO of Quanterix. “Nf-L has the ability to create new testing modalities for detection and treatment across numerous degenerative disease states, including some of the most difficult-to-detect conditions. Our Simoa technology helped researchers measure Nf-L accurately in blood for the first time, and it’s incredibly rewarding to see the continued impact of our technology on these and many other studies.”

This year’s AAN Annual Meeting will feature Nf-L abstracts that assess the viability of the biomarker as a reliable means to detect and monitor a range of neurodegenerative diseases in blood, including Alzheimer’s Disease, MS, ALS, spinal muscular atrophy and Huntington’s. In addition to evaluating the use of serum Nf-L as a comparable marker to traditional cerebral spinal fluid (CSF), presenters will speak to the marker’s drug development benefits for neurodegenerative clinical trials, which continue to face challenges and limitations based on using imaging or cerebrospinal fluid as endpoints. Furthermore, Nf-L is currently included in 46 active clinical trials in the US alone, demonstrating the degree to which its value for monitoring drug response has grown recently.

Quanterix’ Simoa platform is among the technologies proving integral to the study of serum Nf-L for these purposes in large part because it operates at a sensitivity level that is, on average, 1,000 times greater than traditional immunoassays. This dramatic improvement in sensitivity gives researchers unprecedented visibility into the presence of blood-based biomarkers suggestive of various neurological disorders. To date, the company’s technology has been utilized in more than 300 peer-reviewed studies, with more than 170 papers addressing neurological disorders specifically. Findings from this research demonstrate Simoa’s ability to potentially see disease progression earlier than imaging or CSF, improve treatment monitoring, and accelerate the delivery of more effective and safer drugs to market.

To learn more about Quanterix and its biomarker detection solutions, visit AAN Booth 1600. For more information on the AAN abstracts featuring Nf-L and Simoa, click here.

To learn more about Quanterix’ Nf-L assay, click here.

About Quanterix

Quanterix is a company that’s digitizing biomarker analysis with the goal of advancing the science of precision health. The company’s digital health solution, Simoa, has the potential to change the way in which healthcare is provided today by giving researchers the ability to closely examine the continuum from health to disease. Quanterix’ technology is designed to enable much earlier disease detection, better prognoses and enhanced treatment methods to improve the quality of life and longevity of the population for generations to come. The technology is currently being used for research applications in several therapeutic areas, including oncology, neurology, cardiology, inflammation and infectious disease. The company was established in 2007 and is located in Lexington, Massachusetts. For additional Information, please visit https://www.quanterix.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate," "estimate," "intend" and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements in this news release are based on Quanterix’ expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Factors that may cause Quanterix’ actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Quanterix’ filings with the U.S. Securities and Exchange Commission, including the "Risk Factors" sections contained therein. Except as required by law, Quanterix assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.



View source version on businesswire.com: https://www.businesswire.com/news/home/20190506005487/en/

Source: Quanterix Corporation

PAN Communications
Lindsay Poole, 617-502-4300
quanterix@pancomm.com


http://ir.quanterix.com/news-releases/news-release-details/quanterix-simoa-technology-powers-more-85-percent-neurofilament
👍️0

Your Recent History

Delayed Upgrade Clock